Cabometyx trial halted early on success in liver cancer
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Read More
Tag: CELESTIAL
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
